FIELD: biopharmaceuticals.
SUBSTANCE: invention relates to a method of manufacture of a biopharmaceutical medicinal product containing the biomolecule of interest, wherein the method includes: (a) the first phase of manufacture of drug substance from the biomolecule of interest wherein said first phase includes at least one preparation stage chosen from harvest, enrichment wherein said at least one preparation stage in this first phase is conducted with a composition containing at least three amino acids wherein the combination of said at least three amino acids provides for at least one positively charged functional group, at least one antioxidant functional group, at least one osmolyte function and at least one buffer function; and (b) the second phase of further preparation of the drug substance developed in (a) to produce a biopharmaceutical medicinal product, wherein said second phase includes at least one preparation stage chosen from (b1) buffer replacement, (b2) freezing, (b3) unfreezing and (b4) filling; wherein at least one preparation stage at this second phase is conducted with a composition containing (i) at least three amino acids, wherein the combination of said at least three amino acids provides for at least one positively charged functional group, at least one antioxidant functional group, at least one osmolyte function and at least one buffer function; and (ii) one or several sugars, wherein the amino acid/sugar ratio is between 10:1 and 1:100 (in mass).
EFFECT: invention enables manufacture of a biopharmaceutical medicinal product containing the biomolecule of interest.
14 cl, 7 tbl, 30 dwg
Title | Year | Author | Number |
---|---|---|---|
LIQUID COMPOSITION OF POLYPEPTIDES CONTAINING FC DOMAIN OF IMMUNOGLOBULIN | 2011 |
|
RU2600847C2 |
PROTEIN POWDER COMPOSITIONS AND METHODS FOR PREPARING THEM | 2009 |
|
RU2537139C2 |
STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
PHARMACEUTICAL COMPOSITION CONTAINING BIOPHARMACEUTICAL DRUG | 2011 |
|
RU2587056C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ADALIMUMAB | 2014 |
|
RU2664736C2 |
HIGHLY CONCENTRATED COMPOSITIONS OF MONOCLONAL ANTIBODIES | 2013 |
|
RU2711089C2 |
SOLUTION PREPARATION CONTAINING STABILIZED ANTIBODIES | 2011 |
|
RU2653447C2 |
LIQUID PHARMACEUTICAL COMPOSITION | 2015 |
|
RU2719431C2 |
COMPOSITION OF CTLA-4 ANTIBODIES | 2006 |
|
RU2356579C1 |
PHARMACEUTICAL COMPOSITIONS OF HER2 ANTIBODY CONJUGATE | 2020 |
|
RU2795196C2 |
Authors
Dates
2021-03-12—Published
2017-09-15—Filed